Clinical trials: Sunitinib
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02386111
- Testing
- Combination of varlilumab and sunitinib
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Celldex Therapeutics
Differentiated Thyroid Cancer
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Background: BRAFV600E is the most frequent oncogene in differentiated thyroid cancer (DTC) occurring in about 50% of cases. Clinical trials with tyrosine kinase inhibitors (TKI) with specific activity against BRAF in metastatic…
- Trial name
- NCT01700699
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Salerno
Renal Cell Carcinoma
Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear…
- Trial name
- NCT00869011
- Testing
- Endurance exercise
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
Renal Cell Cancer
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.
- Trial name
- NCT00509704
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Metastatic Kidney Cancer
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer. Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of…
- Trial name
- BIOSUNTOX (NCT03846128)
- Testing
- blood sample
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Rouen
Colorectal Neoplasms
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated…
- Trial name
- NCT00609622
- Testing
- sunitinib, mFOLFOX6, bevacizumab
- Where
- 97 sites in United States, Denmark and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Renal Cell Cancer, Colorectal Cancer
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
The purpose of this study is to assess the influence of Sunitinib and Sorafenib on fatigue, quality of life and depression in patients with metastatic renal cell or colorectal cancer or GIST.
- Conditions
- Renal Cell Cancer, Colorectal Cancer, GIST
- Trial name
- NCT00979329
- Testing
- Questionnaires
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Glioblastoma
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Primary Objectives To determine maxi tolerated dose \& dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety \& tolerability of SU011248 + Irinotecan among pts w recurrent MG…
- Trial name
- NCT00611728
- Testing
- SU011248 & Irinotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Renal Cell Carcinoma, GIST
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal…
- Trial name
- NCT00979381
- Testing
- influenza vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Renal Cell Carcinoma, Pulmonary Metastases
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.
- Trial name
- SMAT (NCT01216371)
- Testing
- Sunitinib
- Where
- 11 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Association of Urologic Oncology (AUO)
Cancer, Head and Neck Cancer
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
- Conditions
- Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms
- Trial name
- NCT00437372
- Testing
- Sunitinib, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Renal Cell Carcinoma
A Study for Participants With Metastatic Renal Cell Carcinoma
This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.
- Trial name
- NCT00709995
- Testing
- Enzastaurin, Sunitinib
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 17 people
- Sponsor
- Eli Lilly and Company
Gastrointestinal Stromal Tumors
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including…
- Trial name
- NCT02401815
- Testing
- CGT9486, Pexidartinib, Sunitinib
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Cogent Biosciences, Inc.
Solid Tumors Refractory to Standard Therapy
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors.
- Trial name
- COPS-01 (NCT06940349)
- Testing
- Palbociclib, Sunitinib
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rabin Medical Center
Neuroendocrine Tumors
Treatment With SU11248 in Patients With Neuroendocrine Tumors
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
- Trial name
- NCT00056693
- Testing
- Sunitinib
- Where
- 11 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma
- Trial name
- NCT02068586
- Testing
- Sunitinib, Valproic Acid, Sunitinib Malate
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Renal Cell Carcinoma
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
- Trial name
- NCT00417677
- Testing
- Combination of Temsirolimus and Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 124 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastrointestinal Stromal Tumor, Malignant
Entacapone Combination With Imatinib for Treatment of GIST
This study evaluates the combination of entacapone and imatinib in the treatment of gastrointestinal stromal Tumors who have progressed on the setting of at least Imatinib and Sunitinib.
- Trial name
- NCT04006769
- Testing
- Entacapone, Imatinib Mesylate
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Advanced Solid Tumors, Inoperable
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
The purpose of this study is to select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
- Conditions
- Advanced Solid Tumors, Inoperable, Metastasis
- Trial name
- TSAP (NCT01190241)
- Testing
- desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
- Where
- 2 sites in Netherlands
- Volunteers
- 45 people
- Sponsor
- Amsterdam UMC, location VUmc